Developer docs
API playgroundTry for free, no card

Search company profiles

Lyndra Therapeutics

Full company profile

uuid0000an1

Namestring
Lyndra Therapeutics
Legal namestring
Lyndra Therapeutics, Inc.
Websiteurl
lyndra.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Lyndra Therapeutics was a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, that developed long-acting oral medicines using its proprietary LYNX drug delivery platform. The LYNX platform was designed to transform standard daily oral medications into once-weekly or once-monthly formulations by providing stable dose release at target levels, thereby reducing side effects associated with peak-and-trough drug exposure and improving patient adherence through less frequent dosing. The company's lead product candidate was LYN-005, an investigational oral weekly formulation of risperidone for schizophrenia and other psychiatric conditions requiring long-term medication, which advanced through Phase 3 clinical trials with documented safety, tolerability, and dose release profiles across more than 100 human doses and 1,000 animal doses.

Lyndra operated under a licensing and partnership-driven business model rather than direct commercialization. In December 2023, the company granted Sun Pharmaceutical Industries an exclusive licensing agreement to manufacture and market three of its investigational oral weekly therapies in six countries including Brazil and India, targeting South American and Asia-Pacific markets. The company was backed by a syndicate of life-sciences-focused investors including Polaris Partners, Sarissa Capital, AIG Investments, Gilead Sciences, the Bill & Melinda Gates Foundation, and several Chinese and global healthcare funds, raising approximately $282 million cumulatively across at least seven funding rounds between 2016 and 2023.

Following the $101 million Series E financing in December 2023, the company was unable to sustain operations and ceased to function as an independent entity. In 2025, Innoviva, Inc. acquired the LYNX drug delivery platform for $10.2 million plus up to $20 million in milestones and royalties, transferring the technology to its wholly owned subsidiary Nortiva Bio. The collapse of Lyndra — despite Phase 3 clinical validation and a clinically differentiated technology — illustrates the capital intensity and execution risk inherent in clinical-stage drug delivery platforms seeking to bridge from validation to commercialization.

Short descriptiontext

Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed the proprietary LYNX drug delivery platform to transform daily oral medications into once-weekly or monthly therapies, with lead candidate LYN-005 (oral weekly risperidone) completing Phase 3 trials. The company collapsed in 2025 and sold its LYNX platform to Innoviva.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting oral drug delivery, oral weekly therapies, sustained-release pharmaceuticals, clinical-stage biopharmaceutical, extended-release drug formulations
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Long-acting oral pharmaceuticals
Social media profiles2 records
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lyndra Therapeutics was a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which transforms standard daily pills into once-weekly or monthly oral therapies with sustained drug release. The company's lead product candidate, LYN-005, was an investigational weekly oral formulation of risperidone for the treatment of schizophrenia and other psychiatric conditions requiring long-term medication.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 100+ doses administered in humans across clinical trials
+2 more records
Product overview1 text field

Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed a portfolio of oral weekly therapies enabled by its proprietary LYNX® drug delivery platform. The company's core product was LYN-005 (weekly oral risperidone), which was in late-stage phase 3 clinical trials. The technology transformed standard daily oral medications into sustained-release weekly or monthly formulations. Lyndra Therapeutics ceased operations and its LYNX platform was acquired by Innoviva in 2025.

Product and service1 record
1LYNX Drug Delivery Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-01
Description

Acquired the LYNX drug delivery platform from Lyndra Therapeutics for $10.2 million plus up to $20 million in milestones and royalties. The platform was then transferred to Nortiva Bio, Innoviva's wholly owned subsidiary.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Tris Pharma is a specialty pharmaceutical company focused on long-acting, extended-release, and abuse-deterrent oral drug delivery technologies, making it the closest direct comparable to Lyndra's LYNX platform in mechanism, target customer profile (pharma partners), and formulation-led approach.

TypeDirect peer
Description

Osmotica develops extended-release and specialty oral pharmaceutical products using proprietary osmotic and sustained-release delivery technologies. Comparable to Lyndra as a formulation-driven, long-acting oral therapeutics company targeting CNS and other chronic conditions.

TypeDirect peer
Description

Heron develops long-acting specialty therapeutics using proprietary sustained-release and bioerodible polymer delivery technologies. Comparable to Lyndra in its mission of reducing dosing frequency for chronic conditions and its specialty-pharma commercial model, although Heron's products are injectable rather than oral.

TypeBroad incumbent
Description

Catalent is a global drug delivery and development services provider offering formulation, bioavailability-enhancement, and modified-release technologies for pharma partners. Comparable to Lyndra's underlying drug-delivery engineering capability, though Catalent operates as a broad CDMO serving many partners rather than a single-asset company.

TypeBroad incumbent
Description

Otsuka is a major pharmaceutical company with a leading franchise in long-acting injectable antipsychotics (Abilify Maintena, Abilify Asimtufii, Aripiprazole Lauroxil). Comparable to Lyndra as the dominant incumbent alternative in the long-acting antipsychotic category that LYN-005 (weekly oral risperidone) targets.

TypeBroad incumbent
Description

Johnson & Johnson markets Risperdal Consta (long-acting injectable risperidone) and other depot antipsychotic formulations, making it a direct therapeutic-area competitor to Lyndra's LYN-005 in the long-acting antipsychotic category, though J&J operates a much broader pharmaceutical portfolio.

TypeBroad incumbent
Description

Teva has a substantial specialty and generics franchise with multiple extended-release oral products (including risperidone generics and other modified-release formulations). Comparable to Lyndra as a large-scale producer of long-acting oral therapeutics across CNS and other chronic indications.

TypeEmerging player
Description

Lilly is advancing oral peptide and small-molecule drug delivery (e.g., orforglipron oral GLP-1) using novel formulation and permeation-enhancer technologies. Comparable to Lyndra's mission of enabling oral long-acting therapies, although Lilly operates at vastly greater scale and focuses on metabolic disease.

TypeEmerging player
Description

Novo Nordisk pioneered oral peptide delivery with Rybelsus (oral semaglutide), using a sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) absorption-enhancer platform. Comparable to Lyndra's vision of transforming chronic injectables into oral long-acting therapies, though focused on metabolic indications.

TypeBroad incumbent
Description

Pfizer CentreOne is Pfizer's contract manufacturing and drug delivery services arm offering formulation development and modified-release capabilities to partners. Comparable to Lyndra's platform orientation toward pharma partners needing specialty oral delivery, though at a much broader scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyndra Therapeutics

Long-acting oral pharmaceuticalslyndra.com

Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed the proprietary LYNX drug delivery platform to transform daily oral medications into once-weekly or monthly therapies, with lead candidate LYN-005 (oral weekly risperidone) completing Phase 3 trials. The company collapsed in 2025 and sold its LYNX platform to Innoviva.

What Lyndra Therapeutics does

Lyndra Therapeutics was a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, that developed long-acting oral medicines using its proprietary LYNX drug delivery platform. The LYNX platform was designed to transform standard daily oral medications into once-weekly or once-monthly formulations by providing stable dose release at target levels, thereby reducing side effects associated with peak-and-trough drug exposure and improving patient adherence through less frequent dosing. The company's lead product candidate was LYN-005, an investigational oral weekly formulation of risperidone for schizophrenia and other psychiatric conditions requiring long-term medication, which advanced through Phase 3 clinical trials with documented safety, tolerability, and dose release profiles across more than 100 human doses and 1,000 animal doses.

Lyndra operated under a licensing and partnership-driven business model rather than direct commercialization. In December 2023, the company granted Sun Pharmaceutical Industries an exclusive licensing agreement to manufacture and market three of its investigational oral weekly therapies in six countries including Brazil and India, targeting South American and Asia-Pacific markets. The company was backed by a syndicate of life-sciences-focused investors including Polaris Partners, Sarissa Capital, AIG Investments, Gilead Sciences, the Bill & Melinda Gates Foundation, and several Chinese and global healthcare funds, raising approximately $282 million cumulatively across at least seven funding rounds between 2016 and 2023.

Following the $101 million Series E financing in December 2023, the company was unable to sustain operations and ceased to function as an independent entity. In 2025, Innoviva, Inc. acquired the LYNX drug delivery platform for $10.2 million plus up to $20 million in milestones and royalties, transferring the technology to its wholly owned subsidiary Nortiva Bio. The collapse of Lyndra — despite Phase 3 clinical validation and a clinically differentiated technology — illustrates the capital intensity and execution risk inherent in clinical-stage drug delivery platforms seeking to bridge from validation to commercialization.

Lyndra Therapeutics firmographics

Firmographics
Name
Lyndra Therapeutics
Legal name
Lyndra Therapeutics, Inc.
Website
https://lyndra.com
Company type
Private
Founded year
2015
Operating status
Closed
Headcount range
51–100 employees
Short description
Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed the proprietary LYNX drug delivery platform to transform daily oral medications into once-weekly or monthly therapies, with lead candidate LYN-005 (oral weekly risperidone) completing Phase 3 trials. The company collapsed in 2025 and sold its LYNX platform to Innoviva.
Ownership category
akta.pro rank

Lyndra Therapeutics industry classification

Industry
Product category
Long-acting oral pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLACANAB
Prescription Digital Therapeutics (PDT)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Long-acting oral drug delivery
  • Oral weekly therapies
  • Sustained-release pharmaceuticals
  • Clinical-stage biopharmaceutical
  • Extended-release drug formulations

Where Lyndra Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lyndra Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Distribution channels1 record

Lyndra Therapeutics product offering

Product offering

Core offering

Lyndra Therapeutics was a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which transforms standard daily pills into once-weekly or monthly oral therapies with sustained drug release. The company's lead product candidate, LYN-005, was an investigational weekly oral formulation of risperidone for the treatment of schizophrenia and other psychiatric conditions requiring long-term medication.

Product overview

Lyndra Therapeutics was a clinical-stage biopharmaceutical company that developed a portfolio of oral weekly therapies enabled by its proprietary LYNX® drug delivery platform. The company's core product was LYN-005 (weekly oral risperidone), which was in late-stage phase 3 clinical trials. The technology transformed standard daily oral medications into sustained-release weekly or monthly formulations. Lyndra Therapeutics ceased operations and its LYNX platform was acquired by Innoviva in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • LYNX Drug Delivery Platform

Quantifiable outcome

  • 100+ doses administered in humans across clinical trials
  • +2 more outcomes

Companies that use Lyndra Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Lyndra Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Lyndra Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Innoviva, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Acquired the LYNX drug delivery platform from Lyndra Therapeutics for $10.2 million plus up to $20 million in milestones and royalties. The platform was then transferred to Nortiva Bio, Innoviva's wholly owned subsidiary.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Lyndra Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tris Pharma: Tris Pharma is a specialty pharmaceutical company focused on long-acting, extended-release, and abuse-deterrent oral drug delivery technologies, making it the closest direct comparable to Lyndra's LYNX platform in mechanism, target customer profile (pharma partners), and formulation-led approach.
  • Osmotica Pharmaceutical: Osmotica develops extended-release and specialty oral pharmaceutical products using proprietary osmotic and sustained-release delivery technologies. Comparable to Lyndra as a formulation-driven, long-acting oral therapeutics company targeting CNS and other chronic conditions.
  • Heron Therapeutics: Heron develops long-acting specialty therapeutics using proprietary sustained-release and bioerodible polymer delivery technologies. Comparable to Lyndra in its mission of reducing dosing frequency for chronic conditions and its specialty-pharma commercial model, although Heron's products are injectable rather than oral.

Broad incumbents

  • Catalent: Catalent is a global drug delivery and development services provider offering formulation, bioavailability-enhancement, and modified-release technologies for pharma partners. Comparable to Lyndra's underlying drug-delivery engineering capability, though Catalent operates as a broad CDMO serving many partners rather than a single-asset company.
  • Otsuka Pharmaceutical: Otsuka is a major pharmaceutical company with a leading franchise in long-acting injectable antipsychotics (Abilify Maintena, Abilify Asimtufii, Aripiprazole Lauroxil). Comparable to Lyndra as the dominant incumbent alternative in the long-acting antipsychotic category that LYN-005 (weekly oral risperidone) targets.
  • Johnson & Johnson: Johnson & Johnson markets Risperdal Consta (long-acting injectable risperidone) and other depot antipsychotic formulations, making it a direct therapeutic-area competitor to Lyndra's LYN-005 in the long-acting antipsychotic category, though J&J operates a much broader pharmaceutical portfolio.
  • Teva Pharmaceutical: Teva has a substantial specialty and generics franchise with multiple extended-release oral products (including risperidone generics and other modified-release formulations). Comparable to Lyndra as a large-scale producer of long-acting oral therapeutics across CNS and other chronic indications.
  • Pfizer CentreOne: Pfizer CentreOne is Pfizer's contract manufacturing and drug delivery services arm offering formulation development and modified-release capabilities to partners. Comparable to Lyndra's platform orientation toward pharma partners needing specialty oral delivery, though at a much broader scale.

Emerging players

  • Eli Lilly: Lilly is advancing oral peptide and small-molecule drug delivery (e.g., orforglipron oral GLP-1) using novel formulation and permeation-enhancer technologies. Comparable to Lyndra's mission of enabling oral long-acting therapies, although Lilly operates at vastly greater scale and focuses on metabolic disease.
  • Novo Nordisk: Novo Nordisk pioneered oral peptide delivery with Rybelsus (oral semaglutide), using a sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) absorption-enhancer platform. Comparable to Lyndra's vision of transforming chronic injectables into oral long-acting therapies, though focused on metabolic indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lyndra Therapeutics social profiles

Digital presence

Lyndra Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyndra Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Lyndra Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyndra Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyndra Therapeutics

What does Lyndra Therapeutics do?

Lyndra Therapeutics was a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which transforms standard daily pills into once-weekly or monthly oral therapies with sustained drug release. The company's lead product candidate, LYN-005, was an investigational weekly oral formulation of risperidone for the treatment of schizophrenia and other psychiatric conditions requiring long-term medication.

Is Lyndra Therapeutics a public or private company?

Lyndra Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.

When was Lyndra Therapeutics founded?

Lyndra Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Lyndra Therapeutics based?

Lyndra Therapeutics is headquartered in Watertown, United States, in the North America region.

Who are Lyndra Therapeutics's main competitors?

Direct peers on record are Tris Pharma, Osmotica Pharmaceutical and Heron Therapeutics. Broad incumbents are Catalent, Otsuka Pharmaceutical, Johnson & Johnson, Teva Pharmaceutical and Pfizer CentreOne. Emerging players are Eli Lilly and Novo Nordisk.

Does Lyndra Therapeutics have an API?

No public API is recorded for Lyndra Therapeutics.

What industry is Lyndra Therapeutics in?

Lyndra Therapeutics's product category is Long-acting oral pharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLACANAB, Prescription Digital Therapeutics (PDT). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comInnoviva earnings up next: Can LYNX platform pivot pay off? By Investing.comInnoviva Inc. is reporting second-quarter earnings on Wednesday, with analysts expecting EPS of 43 cents on revenue of $110.9 million, representing 10.6% year-over-year revenue growth but a 44.7% decline in earnings per share. The company launched Nortiva Bio in mid-June as a wholly owned subsidiary to develop long-acting oral medicines using its LYNX drug delivery platform, which Innoviva acquired from Lyndra Therapeutics for $10.2 million last September. Investors will scrutinize whether the company's royalty business from GlaxoSmithKline respiratory products can sustain growth while offsetting incremental R&D spending of $4-5 million annually from the new subsidiary.GurufocusNortiva Bio Launches to Develop Long-Acting Oral MedicinesNortiva Bio, Inc. announced its launch as a clinical-stage biopharmaceutical company developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which can transform daily pills into therapies with single doses lasting up to a month. The company is a wholly owned subsidiary of Innoviva, Inc., which acquired the LYNX platform from Lyndra Therapeutics in 2025, and has formed an advisory board including prominent figures from MIT and former FDA officials. Nortiva's lead development program includes a once-monthly oral contraceptive being advanced with a $5 million Gates Foundation grant, while the company is also building a partnering pipeline with biotech and pharmaceutical companies.Business Wire BlogNortiva Bio Launches to Develop Long-Acting Oral MedicinesNortiva Bio, Inc. launched as a clinical-stage biopharmaceutical company in Lexington, Massachusetts, dedicated to developing long-acting oral medicines using its proprietary LYNX drug delivery platform, which can transform daily pills into therapies with single doses lasting up to a month. The company is a wholly owned subsidiary of Innoviva, Inc., which acquired the LYNX platform from Lyndra Therapeutics in 2025, and has already demonstrated clinical proof of concept across multiple therapeutic areas including a successful Phase 3 study. Nortiva is advancing a lead oral contraceptive program with a $5 million Gates Foundation grant while simultaneously building a partnering business with biotech and pharmaceutical companies to develop long-acting oral versions of approved and pipeline small-molecule therapies.FierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupInnoviva has launched Nortiva Bio, a wholly owned subsidiary, to develop long-acting oral medicines using the Lynx drug delivery platform it acquired for $10.2 million from collapsed Lyndra Therapeutics. Nortiva's lead asset is a monthly oral contraceptive backed by a $5 million Gates Foundation grant, with MIT professor Robert Langer and former FDA commissioner Janet Woodcock joining its advisory board. The company also plans to build partnered programs by pitching the Lynx platform to businesses seeking long-acting oral versions of existing drugs.FiercePharmaNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupInnoviva has created a new subsidiary, Nortiva Bio, to develop long-acting oral medicines using the Lynx drug delivery platform it acquired from collapsed Lyndra Therapeutics for $10.2 million in a deal including up to $20 million in milestones and royalties. Nortiva's lead asset is a monthly oral contraceptive backed by a $5 million Gates Foundation grant targeting women in low- and middle-income countries, with an advisory board featuring MIT professor Robert Langer and former FDA commissioner Janet Woodcock. The company plans to build a partnered pipeline offering businesses long-acting oral versions of approved or development-stage small molecule drugs.Technology NetworksOnce-Weekly Oral Risperidone Shows Promise in Schizophrenia TreatmentA Phase 3 clinical trial in the US evaluated LYN-005, a once-weekly oral formulation of risperidone developed by Lyndra Therapeutics, demonstrating that it maintains stable drug levels comparable to daily dosing while potentially reducing side effects. The study involved 83 adults with schizophrenia or schizoaffective disorder and confirmed the viability of the star-shaped capsule delivery technology for long-acting oral administration. Researchers note that larger, randomized trials are needed to validate adherence benefits and broader applicability.Business Wire BlogLyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral TherapiesLyndra Therapeutics announced a collaboration with Thermo Fisher Scientific for clinical research and commercial manufacturing services for its long-acting oral therapies. Thermo Fisher will support the phase 3 pivotal safety study of oral weekly risperidone (LYN-005), set to begin in 1H 2025, and commercial manufacturing using Lyndra's LYNX platform.Pulse 2.0Lyndra Therapeutics: Clinical-Stage Biopharmaceutical Company Closes $101 MillionLyndra Therapeutics closed a $101 million Series E financing round led by Sarissa Capital, with participation from Sun Pharmaceutical Industries Limited and Polaris Partners. The funding will support the development of its LYNX drug delivery platform pipeline, specifically the oral weekly risperidone candidate which is nearing phase 3 completion. As part of the deal, Sun Pharma secured an exclusive license to manufacture and market three investigational therapies in six countries including Brazil and India.FinSMEsLyndra Therapeutics Raises $101M in Series E FundingLyndra Therapeutics raised $101M in Series E funding led by Sarissa Capital, with Sun Pharma and Polaris Partners participating. The company will use the funds for its pipeline, including oral weekly risperidone (LYN-005) near completion of a pivotal phase 3 study.Venture Capital Access OnlineLyndra Therapeutics Raises $101 Million in Series E FundingLyndra Therapeutics closed a $101 million Series E funding round led by Sarissa Capital, with participation from Sun Pharmaceutical Industries Limited and Polaris Partners. The capital will support the development of its LYNX drug delivery platform, including pivotal Phase 3 trials for oral weekly risperidone. Concurrently, Sun Pharma secured an exclusive license to market three of Lyndra's clinical candidates in six global markets.